These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26342296)

  • 1. Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.
    Hur JW; Choe JY; Kim DW; Kim HA; Kim SH; Kim WU; Kim YS; Lee HS; Lee SH; Park SH; Park W; Park YB; Suh CH; Shim SC; Song YW; Yoon BY; Yu DY; Yoo DH
    Rheumatol Int; 2015 Nov; 35(11):1817-23. PubMed ID: 26342296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria.
    Geens E; Geusens P; Vanhoof J; Berghs H; Praet J; Esselens G; Lens S; Dufour JP; Vandenberghe M; Van Mullem X; Westhovens R; Verschueren P
    Rheumatology (Oxford); 2009 May; 48(5):546-50. PubMed ID: 19254920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
    Fautrel B; Flipo RM; Saraux A
    Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
    Deighton C; Hyrich K; Ding T; Ledingham J; Lunt M; Luqmani R; Kiely P; Bukhari M; Abernethy R; Ostor A; Bosworth A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2010 Jun; 49(6):1197-9. PubMed ID: 20308121
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.
    Bingham SJ; Buch MH; Tennant A; Emery P
    Rheumatology (Oxford); 2004 Mar; 43(3):364-8. PubMed ID: 14657509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
    Pocock JM; Vasconcelos JC; Ostör AJ
    Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register.
    McWilliams DF; Walsh DA
    BMC Musculoskelet Disord; 2016 Aug; 17():337. PubMed ID: 27515300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.